Kolmar patriarch wants shares gifted to son back amid sibling rivalry
In a dramatic and unprecedented legal move that has shaken South Korea’s corporate landscape, Kolmar Group founder and Chairman Yoon Dong-han ...
S.Korea’s CDMO giant Samsung Biologics to offer CRO services
Samsung Biologics Co., the world’s largest contract drugmaker, will enter the contract research organization (CRO) market by leveraging its va...
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
SK Hynix makes strides in CXL technology, escalating rivalry
SK Hynix Inc., the leading global high-bandwidth memory (HBM) chip provider, has moved faster than its rivals in the commercialization of the next-g...
SillaJen: First to use lab-grown human tissue to find best cancer drug dose
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...
South Korea to levy 38% anti-dumping duties on Chinese steel products
South Korea plans to impose up to 38% provisional anti-dumping duties on Chinese hot-rolled steel plates starting next month, judging that those pro...
China likely to lift ban on South Korea’s K-wave as early as May
BEIJING – China will likely lift its ban on Hallyu, or Korean popular culture in the country, as early as May, moving away from its “wol...
Korean bakery giant SPC to build $160 mn US plant as tariff war escalates
SPC Group, the operator of South Korea’s largest bakery chain Paris Baguette as well as Paris Croissant, SPL, Dunkin and SPC GFS, is building ...
Mediaiplus aims to be the Amazon of clinical trials
Mediaiplus Inc., South Korea’s only provider of data analytics and contract research organization (CRO) matching services for clinical trials,...
HD Hyundai may nearly double shipbuilding capacity in Vietnam
HD Hyundai Co., the world’s second-largest shipbuilder, is likely to nearly double its vessel construction capacity in Vietnam to meet surging...
S.Korea’s premium kimchi war escalated by luxury hotels
Kimchi, Koreans’ staple food throughout millennia, has become a new, lucrative revenue source for the country’s luxury hotel chain opera...
LG’s telecom unit looks to lure foreigners with more K-pop-themed shops
LG Uplus Corp., South Korea’s No. 3 mobile carrier, is set to lure foreign customers by opening K-pop-themed stores in the country's major sho...
Celltrion gets FDA nod for Keytruda copy's phase 3 clinical trials
Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, ...
Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman
WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...
HYBE conflict vs NewJeans label set to escalate into legal battle
HYBE Co., the company behind boy band BTS, has reported Min Hee-jin, the chief of popular girl group NewJeans’ label ADOR, to police for inves...
Samsung gains upper hand vs Netlist in $303 million patent dispute
Samsung Electronics Co. has taken the upper hand in its ongoing legal battle against Netlist Inc. over memory chip module patent infringement allega...
Global quest to find modern elixirs enters new chapter
NEW YORK/ BOSTON – Longevity has long been the dream of humankind. China’s first emperor Qin Shi Huang was obsessed with finding magic e...
SK Bioscience exports Sky Cellflu to Thailand
South Korea's SK Bioscience Co. announced on Thursday that it has shipped about 440,000 doses (for single-dose administration) of its cell-cultured ...
Aprogen gets OK Phase 3 trials in India for Herceptin biosimilar
South Korea’s biopharmaceutical company Aprogen Inc. announced on Monday that its Phase 3 clinical trial for a biosimilar of Herceptin (trastu...
JW Pharma takes gout drug Epaminurad to Malaysia for phase 3
South Korea's JW Pharmaceutical Corp., announced on Monday that it has received approval from the Malaysian National Pharmaceutical Regulatory Age...
LG Chem out-licenses obesity drug candidate to US firm
LG Chem Ltd. has agreed to license out a rare genetic obesity drug candidate in phase 2 clinical trials to Rhythm Pharmaceuticals Inc., a US biotech...
MedPacto gets FDA OK for colorectal cancer drug clinical trial
South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its I...
CGBio gets FDA approval for Novosis Putty
South Korea's bio-regenerative medical firm CGBio announced on Tuesday that its Novosis Putty has been designated as a breakthrough device by the US...
MBK raises Hankook bid price, asks FSS to probe Cho's stock purchase
The sibling rivalry for control of Hankook & Company Co., the holding firm of South Korea’s largest tire maker Hankook Tire & Techno...
SK Bioscience applies Phase 3 trials in US for pneumococcal vaccine
South Korea's SK Bioscience Co. announced on Monday that it submitted the Investigational New Drug (IND) application for the Phase 3 clinical trial ...
Celltrion applies for approval in Europe for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...
NKMax to perform first tests on dementia cell therapy in US
NKMax Co., South Korea's largest developer of natural killer (NK) cell therapies, will conduct its first clinical trials in the US for its candidate...
Hanmi Pharma’s Phase 3 trials for anti-obesity medicine approved
South Korea’s Hanmi Pharmaceutical Co. on Monday said the Ministry of Food and Drug Safety approved Phase 3 clinical trials for the company&...
Humedix gets gov't OK for trials of dementia candidate drug
South Korea’s Humedix Co., a developer of biological and pharmaceutical products, on Tuesday said it received approval from the Ministry of Fo...
NKMax's US subsidiary listed on Nasdaq
South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...
